Patients with central retinal vein occlusion (CRVO) who received aflibercept achieved significant improvement in visual acuity, compared with those receiving sham treatment in 2 phase 3 clinical trials. Researchers presented the trial results at the 12th European Society of Retina Specialists (EURETINA) Congress in Milan, Italy. Last week, on the basis of these 2 trials, the US Food and Drug Administration approved the drug for use in patients with CRVO. The drug blocks the vascular endothelial growth-factor (VEGF) pathway, decreasing vascular permeability and edema in the retina.To see more details visit, www.medscape.com